Hema Renew, New disclosure details a 500 mg proprietary blend of arginine- and citrulline-related compounds and explains why gram-level research cannot be directly applied to the finished supplement

LARGO, Fla. — October 5, 2026 — Hema Renew has published the current label specifications for its three-amino-acid dietary supplement, providing additional context on its 500 milligram proprietary blend and the limitations of comparing the finished capsule with published research involving individual arginine and citrulline compounds.

According to the current Supplement Facts information, one capsule contains a proprietary blend of L-arginine HCl, L-arginine alpha-ketoglutarate and L-citrulline malate. The combined blend weighs 500 milligrams per capsule, but the label does not state how much of each individual compound is included.

The label directs adults to take one capsule daily with eight ounces of water and permits up to two capsules daily. At the highest labeled serving, the combined proprietary blend totals 1,000 milligrams, or 1 gram.

That figure provides an important point of context when comparing the label with published ingredient research. Human studies involving arginine and citrulline frequently use quantities measured in grams rather than hundreds of milligrams, and the studies cited by the company did not evaluate the HemaRenew Blood Optimizer formulation itself.

Hema Renew states that no clinical trial has evaluated the finished capsule and that the product should not be interpreted as a substitute for prescribed treatment for high blood pressure or any other medical condition.

“People should be able to distinguish what appears on a supplement label from what was actually tested in published research,” said Kevin Moore, Product Head at Hema Renew. “The blend total is disclosed, but individual ingredient amounts are not, and the research used different formulations, doses and participant groups.”

What the Current Label Discloses

The Supplement Facts panel identifies a proprietary blend containing three amino-acid-related compounds:

L-arginine HCl, L-arginine alpha-ketoglutarate and L-citrulline malate. Other listed ingredients include gelatin in the capsule shell, rice flour and magnesium stearate. One bottle contains 60 capsules.

A proprietary blend identifies the combined quantity of a formulation while allowing the amounts of the individual ingredients within that formulation to remain undisclosed.

For Hema Renew, the combined quantity is 500 milligrams in one capsule. That means a consumer can determine the total amount of all three compounds but cannot determine the precise amount of L-arginine HCl, L-arginine alpha-ketoglutarate or L-citrulline malate individually.

The distinction matters when comparing the supplement with scientific literature. A clinical study evaluating a specific quantity of L-arginine, for example, cannot be directly compared with a multi-ingredient proprietary blend when the amount of L-arginine in that blend is unknown. The same limitation applies to citrulline.

Different Forms of Arginine and Citrulline

The three ingredients listed in the proprietary blend are related but are not interchangeable. L-arginine HCl is a salt form of the amino acid arginine.

L-arginine alpha-ketoglutarate combines arginine with alpha-ketoglutarate, a compound involved in metabolic processes. L-citrulline malate combines the amino acid citrulline with malate. Citrulline can be converted by the body into arginine through normal metabolic pathways.

Research involving one of these compounds does not automatically establish the effects of another form. Differences in chemical form, dose, duration of use and study population all affect whether two products or research findings can reasonably be compared.

For that reason, Hema Renew says the presence of an ingredient name on its label should not be interpreted as evidence that the finished capsule produces the outcomes reported in studies involving that ingredient.

Gram-Level Research Provides Context for the 500 mg Blend

One of the clearest differences between the label and published research is the unit of measurement.

The Hema Renew blend contains 500 milligrams per capsule. At the maximum labeled serving of two capsules, the complete blend equals 1,000 milligrams, or 1 gram.

The studies reviewed by the company commonly evaluated individual ingredients at several grams per day.

That does not establish whether the finished HemaRenew Blood Optimizer product is effective or ineffective. It does show that the quantities and formulations used in published research are materially different from the disclosed total weight of the finished proprietary blend.

Because the blend is divided among three compounds, none of the individual ingredient amounts can be calculated from the label.

Even in the hypothetical situation where the entire blend consisted of one ingredient, the highest labeled serving would equal approximately 1 gram, below the amounts used in many of the studies cited in the company’s research summary.

In reality, the blend contains three ingredients, making direct dose comparisons even less precise.

Published Research on L-Arginine

A 2011 meta-analysis published in the American Heart Journal examined randomized clinical trials involving oral L-arginine supplementation and blood pressure.

The analysis included 11 trials with a combined 383 participants.

Researchers reported average reductions of approximately 5 millimeters of mercury in systolic blood pressure and approximately 3 millimeters of mercury in diastolic blood pressure across the pooled studies.

However, the doses used in the reviewed trials ranged from approximately 4 grams to 24 grams of L-arginine per day.

The trials were also relatively small and short in duration.

Those quantities are substantially greater than the total weight of the HemaRenew Blood Optimizer proprietary blend, which is 500 milligrams per capsule.

The comparison does not establish what amount of L-arginine is present in Hema Renew because the individual ingredient quantities are not disclosed.

It therefore cannot be assumed that results observed at gram-level doses of L-arginine would occur with the finished supplement.

Research Has Also Identified Important Safety Context

Arginine research has not produced uniformly positive findings.

A randomized clinical trial published in JAMA in 2006 evaluated L-arginine supplementation in approximately 150 people following myocardial infarction.

Participants received L-arginine in addition to standard medical treatment.

Researchers did not find improvement in the vascular measurements being studied, and the trial was stopped after more deaths occurred in the arginine group than in the placebo group.

The investigators did not recommend L-arginine supplementation for that patient population.

That trial involved a particular medical group and should not be generalized to all adults or all uses of arginine.

It does, however, illustrate why supplement research should be interpreted according to the population, dose and clinical circumstances in which it was conducted.

HemaRenew Blood Optimizer states that people with cardiovascular conditions should consult a qualified healthcare professional before using amino-acid supplements.

Published Research on L-Citrulline

Citrulline has also been studied in relation to cardiovascular measurements.

A systematic review and meta-analysis published in the Avicenna Journal of Phytomedicine in 2019 evaluated clinical trials of L-citrulline supplementation.

The pooled analysis reported a small reduction in systolic blood pressure.

However, the individual studies were relatively small and differed in participant characteristics, duration and dose.

The review evaluated citrulline supplementation generally and did not evaluate HemaRenew or its combination of ingredients.

Because the Hema Renew label does not state the amount of L-citrulline malate in each capsule, the published doses cannot be directly matched with the product.

Citrulline Malate Research Has Also Focused on Exercise

Not all research involving citrulline malate concerns blood pressure.

A study published in the Journal of Strength and Conditioning Research in 2010 evaluated a single 8-gram dose of citrulline malate in 41 men before resistance exercise.

Researchers reported differences in exercise repetitions and post-exercise muscle soreness.

The research involved exercise performance rather than treatment of hypertension or another cardiovascular condition.

The 8-gram dose was also substantially greater than the entire 500-milligram proprietary blend contained in one HemaRenew capsule.

The study therefore provides information about a particular dose of citrulline malate under specific exercise conditions rather than evidence about Hema Renew.

Research on Arginine Alpha-Ketoglutarate

Arginine alpha-ketoglutarate has similarly been investigated in sports and exercise settings.

A trial published in Nutrition evaluated trained adult men who received approximately 12 grams per day of L-arginine alpha-ketoglutarate over eight weeks.

Researchers reported differences in some strength and power measurements.

The study did not investigate treatment of high blood pressure and did not evaluate the HemaRenew formulation.

The dosage was also many times greater than the complete daily proprietary-blend amount listed on the Hema Renew label.

Ingredient Evidence Is Not Finished-Product Evidence

The company says its new disclosure is intended to make one distinction particularly clear: scientific evidence associated with an individual ingredient should not automatically be presented as evidence for a finished multi-ingredient product.

Several factors can prevent a direct comparison.

These include ingredient quantity, chemical form, manufacturing method, participant population, health status, duration of use and the particular outcome measured.

A study may also involve a single ingredient while a commercial supplement contains several ingredients.

In Hema Renew’s case, the product contains three compounds within one proprietary blend, and the individual amounts are not disclosed.

HemaRenew states that no published clinical trial has evaluated the finished formulation.

Accordingly, the company is not claiming that Hema Renew lowers blood pressure, treats hypertension or produces the findings reported in the individual studies.

Blood Pressure Should Be Measured, Not Inferred From Symptoms

The company’s publication also addresses the distinction between supplement use and medical management of hypertension.

High blood pressure can occur without noticeable symptoms.

For that reason, a person’s physical feelings are not a reliable way to determine whether blood pressure is within a healthy range.

Clinical guidelines recommend measuring blood pressure and, where appropriate, confirming readings outside a medical office.

Treatment decisions may include lifestyle changes, medication or both depending on the person’s cardiovascular risk and blood-pressure readings.

HemaRenew states that consumers should not stop, reduce, skip or otherwise change prescribed blood-pressure medication because they begin taking a dietary supplement.

Any change in treatment should be discussed with the prescribing healthcare professional.

Medication and Health Considerations

Arginine and citrulline may be relevant for people using medicines that affect blood pressure or circulation.

The company advises consumers taking blood-pressure medicines, nitrate medicines, blood thinners, diabetes medicines or other medications to speak with a qualified healthcare professional before using the product.

Medical guidance may also be appropriate for people with heart disease, kidney conditions or a history of heart attack.

People preparing for surgery should inform their medical team about dietary supplements they use because some supplement ingredients can affect blood pressure, circulation or medication management.

The company also advises people who are pregnant, nursing or under 18 not to use the supplement without appropriate medical guidance.

Similar Product Names Can Create Label Confusion

Hema Renew says online search results may include websites, marketplace listings or products with similar names but different formulas. For that reason, the company advises consumers to compare online product descriptions against the current physical package.

The Supplement Facts panel should be used to verify the ingredients, serving size and total proprietary-blend quantity. Information appearing in old articles, reviews, marketplace listings or third-party product descriptions may not reflect the current label.

This is particularly important with proprietary blends because even a small change in formulation can affect whether older ingredient descriptions remain accurate.

FDA Regulation and Supplement Labels

Consumers should also distinguish between manufacturing requirements and regulatory approval.

The U.S. Food and Drug Administration does not approve dietary supplements for safety and effectiveness before they are marketed in the same way it approves prescription drugs.

Statements that a product is manufactured in a facility following Good Manufacturing Practice requirements do not mean that the finished dietary supplement has been FDA-approved.

Likewise, an ingredient’s appearance in scientific literature does not constitute FDA approval of a finished commercial product containing that ingredient.

The company says consumers should evaluate supplements using the current label, available scientific evidence and advice from qualified healthcare professionals rather than relying on isolated marketing statements.

Why Dose Context Matters in Supplement Research

The HemaRenew disclosure reflects a broader challenge in consumer interpretation of supplement research.

Scientific studies typically identify a precise ingredient, dose, treatment duration and participant population.

Commercial proprietary blends may disclose the total formulation weight without identifying individual quantities.

As a result, two products containing the same named ingredient can differ substantially in concentration and formulation.

The presence of L-arginine on a Supplement Facts panel, for example, does not establish that the product provides the 4 to 24 grams per day examined in the blood-pressure studies summarized in the company’s review.

Similarly, the presence of L-citrulline malate does not establish that a capsule contains the 8 grams examined in an exercise study.

The correct conclusion is not necessarily that a smaller amount has no biological activity. Instead, the available label information does not provide evidence that the commercial formulation is equivalent to the formulations and doses used in the cited studies.

That distinction is central to interpreting dietary-supplement research accurately.

About Hema Renew

Hema Renew is a U.S.-marketed capsule dietary supplement containing a proprietary formulation of L-arginine HCl, L-arginine alpha-ketoglutarate and L-citrulline malate. The current Supplement Facts information lists a 500-milligram proprietary blend per capsule. One bottle contains 60 capsules.

The company states that its product label should be used as the primary source for current ingredient, serving and usage information and that research involving individual ingredients should not be interpreted as clinical evidence for the finished formulation.

Media Contact

Kevin Moore
Product Head, Hema Renew
11870, 62nd St N, Largo, FL 33773
Email: support@myhemarenew.online

Website: myhemarenew.online

References

Whelton PK, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Journal of the American College of Cardiology, 2018.

Dong JY, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. American Heart Journal, 2011.

Schulman SP, et al. L-arginine therapy in acute myocardial infarction: The VINTAGE MI randomized clinical trial. JAMA, 2006.

Barkhidarian B, et al. Effects of L-citrulline supplementation on blood pressure: a systematic review and meta-analysis. Avicenna Journal of Phytomedicine, 2019.

Pérez-Guisado J, Jakeman PM. Citrulline malate enhances athletic anaerobic performance and relieves muscle soreness. Journal of Strength and Conditioning Research, 2010.

Campbell B, et al. Research examining the pharmacokinetics, safety and exercise-related effects of L-arginine alpha-ketoglutarate in trained adult men. Nutrition, 2006.

MedlinePlus, U.S. National Library of Medicine. Arginine.

U.S. Food and Drug Administration. Dietary Supplement Labeling Guide.

Disclaimer: Hema Renew states that no clinical trial has evaluated the finished product. Research involving individual ingredients, different doses or different formulations does not establish the effectiveness of the Hema Renew capsule. The product is not intended to diagnose, treat, cure or prevent disease and should not replace prescribed medication or professional medical care.

About The Author
Hema Renew